Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
New Weight Loss Drug CagriSema Shows Impressive Results in Clinical Trials CagriSema is a once-weekly injection of semaglutide and cagrilintide
This absence of negative interactions supports the safety of combination approaches
A key differentiator of Mardrigals resmetirom is that in a pivotal Phase 3 trial, it achieved both primary endpoints of NASH resolution and reduction in fibrosis (MAESTRO-NASH), the two liver histological improvement endpoints the FDA has proposed as reasonably likely to predict clinical benefit
Since the FDA approved the first GLP-1 medicationByetta (exenatide)in 2005, clinicians have observed that GLP-1s not only support blood sugar control but also contribute to weight loss and other metabolic health improvements
Rangaraju V, Calloway N, Ryan TA
US$ 22.29
US$ 22.30
US$ 24.41
